Stage IB lung adenocarcinoma
Conditions
Interventions
DetermaRx molecular model prediction group:
Sponsors
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with lung adenocarcinoma resected by R0; 2. Stage IB (eighth TNM stage); 3. Complete clinical data and follow-up information; 4. Age >= 18 years; 5. Pulmonary lobectomy plus systematic lymph node dissection; 6. FFPE samples required for testing are available.
Exclusion criteria
Exclusion criteria: 1. Received neoadjuvant therapy before surgery; Postoperative radiotherapy was performed; 2. Incomplete follow-up information and lost follow-up; 3. Patients who had cancer other than NSCLC within the five years prior to the initiation of treatment in this study. Carcinoma in situ of the cervix cured basal cell carcinoma, bladder epithelial neoplasms (including Ta and Tis) were excluded; 4. Sublobectomy (wedge resection, segmental resection), lymph node sampling; 5. Moderate to severe organ dysfunction except for tumor; 6. Other conditions considered unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival time; | — |
Countries
China
Contacts
Public ContactWenyong Zhou
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Outcome results
None listed